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Abstract 
 
Background  
Left ventricular assist devices (LVAD) are an increasingly used therapy for patients 
with advanced heart failure. Arrhythmias are common complications following 
LVAD implantation requiring admission, initiation, and escalation of medical 
therapy. Despite their frequent use in the treatment of arrhythmias, little has been 
reported regarding electrocardiographic changes, antiarrhythmic utilization, and 
outcomes post-LVAD.  
Methods  
 
A total of 309 patients who received a LVAD underwent retrospective chart review 
pre- and post-LVAD. Kaplan-Meier curves were calculated and compared using 
the log-rank test. Cox regression model was used for univariate analysis and those 
with a p<0.15 were included in multivariate analysis to evaluate for overall survival.  
 
Results  
 
There was a significant reduction in both the QRS interval (p=0.0001) and QTc 
interval (p=0.0074) following LVAD implantation. Ventricular tachycardia is 
common following LVAD implant at 31.1%. Amiodarone use was frequent prior to 
LVAD (52.1%) and on discharge (68.6%). Amiodarone use (p=0.019, HR 1.7, 95% 
CI 1.1-2.6), age at implant (p<0.001), creatinine (p=0.004), albumin (p=0.02), red-
cell distribution width (p=0.047), and prior median sternotomy (p<0.0001), were 
associated with increased mortality. On multivariate analysis, only albumin 
(p=0.013) and prior median sternotomy (p<0.001) remained statistically significant. 
There was no significant difference in post-operative duration of intubation, 
number of readmissions, or length of stay base on amiodarone utilization. 
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Conclusions 
 
Amiodarone is a commonly used antiarrhythmic in advanced heart failure and its 
use prior to LVAD implantation may increase the risk of long-term mortality. The 
amiodarone  efficacy needs to be weighed against its long-term side effects and 
implant on clinical outcomes.   
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Introduction  
 
While treatments for heart failure have improved over the last two decades, the 
number of patients with advanced heart failure who are or become refractory to 
standard medical therapy continues to increase. Heart transplantation alone is not 
possible for a large proportion of this increasing population of patients, due to an 
overall plateau in the number of organs available for transplantation worldwide as 
well as patient-specific factors making them poor candidates for heart 
transplantation. With the continued development and improvement in left 
ventricular assist device (LVAD) design, along with decreased morbidity and 
mortality post-implantation, the incidence of new device implantations not only as 
bridge to transplantation (BTT), but also as destination therapy (DT) has 
significantly increased over the last 15 years.1 Arrhythmias, especially ventricular 
arrhythmias, are a common post-LVAD complication, with an incidence ranging 
from 22-59% and are frequently better tolerated in LVAD patients due to their 
ability to maintain cardiac output when perturbations in heart rate and ventricular 
synchrony are present.2, 3  
 
Appropriate treatment of arrhythmias after LVAD implantation havs not been 
completely defined and have only been reported in a couple of small, retrospective 
studies.4, 5 While antiarrhythmic medications are frequently used to treat both atrial 
and ventricular arrhythmias in LVAD patients, the use of these agents and the 
outcomes associated with their used have not been adequately described. The 
purpose of this study was to determine common rhythms/arrhythmias and 
electrocardiographic (ECG) changes related to LVAD implantation as well as 
antiarrhythmic utilization to treat these arrhythmias and how these impact 
outcomes following implantation.  
 
Methods  
 
Study Population 
 
We conducted a retrospective chart review of 309 patients who underwent LVAD 
implantation as BTT or DT at The University of Nebraska Medical Center between 
July 2004 and October 2017. This involved a full review of the patient's electronic 
health records (EHR), including physician progress notes, nursing notes, telemetry 
records, and implantable cardioverter defibrillator (ICD) interrogations, evaluating 
for documented evidence of atrial or ventricular arrhythmias as well as patient's 
medication administration records to document prescribing of antiarrhythmic 
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medications. Records were reviewed from the time of first preoperative evaluation 
by our cardiology or cardiothoracic surgery team and followed postoperatively until 
death, heart transplant, or completion of data collection on November 27th, 2017. 
The study was approved by the institutional review board at our institution.  
 
Clinical Variables 
 
We obtained demographic and clinical variables on patients undergoing LVAD 
implantation via review of the EHR. These variables included age, gender, left 
ventricular ejection fraction (LVEF), left ventricular internal diameter end diastole 
(LVIDd), ICD status, routine laboratory values (e.g. potassium, creatinine, albumin, 
etc.), antiarrhythmic therapy and other drug therapy pre- and post-LVAD 
implantation, and other pertinent medical history (e.g. presence of arrhythmias, 
pre-implantation comorbidities, etc.).  
 
Ventricular tachycardia (VT) was defined as sustained or non-sustained VT 
(NSVT) with symptoms requiring antiarrhythmic therapy. Preoperative VT and 
atrial fibrillation (afib) were defined as documentation within clinical notes, 
telemetry records, or ECG of VT or afib prior to LVAD implantation. Postoperative 
VT or afib were defined as documented VT or afib within clinical notes, telemetry 
records, or ECG following LVAD implantation. 
 
Pre- and post-LVAD ECG intervals (PR, QRS, QT, and QTc) and rhythms were 
obtained via review of each ECG documented in the patient's EHR. Both 
ventricular-paced and non-paced rhythms and intervals were documented for 
comparison between pre- and post-implantation periods.  
 
Statistical Analysis 
 
Descriptive statistics included counts and percentages for categorical data and 
means and standard deviations for continuous data. The independent sample t-
test was used to compare continuous measures between groups. Overall survival 
(OAS) was defined as the time from implant to time of death from any cause. 
Patients who underwent heart transplantation were censored at the time of 
transplant and patients who underwent LVAD explantation or defunctionalization 
were censored at the time of this surgery. The OAS curve was calculated using the 
Kaplan-Meier method and compared using the log-rank test. Confidence interval 
for estimate of time-to-event distribution was calculated using Greenwood's 
formula. The Cox regression model for censored data was used to examine patient 
characteristics of OAS in a univariate analysis. Factors significant on univariate 
analysis (p < 0.15) were included in the multivariate analysis. For secondary 
outcomes, Fisher's exact test was used to compare intubation at 24 hours 
between groups and the Mann-Whitney test was used to compare the median LOS 
and hospital readmissions between groups. A p-value of <0.05 was considered 
statistically significant.  
 
Results  
Our study population included 309 patients, 240 (77.7%) were males and the 
mean age was 56.7 (12.9) years. Destination therapy was the implant strategy for 
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187 (60.5%) patients and 163 (52.7%) had ischemic cardiomyopathy. The mean 
left ventricular ejection fraction (LVEF) was 17.9% (8.9) and mean left ventricular 
internal dimension in diastole (LVIDd) was 64.7 mm (9.1). Patients on amiodarone 
prior to LVAD implantation tended to be older (59.2 vs 54 years, p<0.0001), more 
likely female (25.8% vs 18.7%, p=0.04), have a history of chronic obstructive 
pulmonary disease (27% vs 16.7%), have a higher creatinine (1.37 vs 1.25, 
p=0.01), lower albumin (3.27 vs 3.31, p=0.04), and have higher prevalence of 
ventricular tachycardia (62.9% vs 24.7%, p<0.0001) and atrial fibrillation (71.7% vs 
38%, p<0.0001). Full pre-LVAD clinical characteristics are shown in Table 1.  
 
Table 1. Pre-LVAD Implantation Patient Characteristics and Hemodynamics 
 
Characteristic Total 
population, 
N=309 
Pre-LVAD 
Amiodarone, 
N=159 
No Pre-LVAD 
Amiodarone, N= 
150 
p-value 
Age, y (SD) 56.7 (12.9) 59.2 (11.7) 54.0 (13.7)  <0.0001 
Female Sex, N (%) 69 (22.3) 41 (25.8) 28 (18.7) 0.04 
BTT Implant Strategy, N (%) 187 (60.5) 92 (57.9) 96 (64) 0.29 
Pre-LVAD BMI, kg/m2 (SD) 30.1 (6.6) 29.69 (5.4) 30.40 (7.9) 0.99 
Ischemic Cardiomyopathy, N (%) 163 (52.8) 88 (55.3) 74 (49.3) 0.54 
Baseline LVEF, % (SD) 17.9 (8.9) 19.5 (10.3) 17 (8.4) 0.034 
Baseline LVIDd, mm (SD) 64.7 (9.1) 64.1 (9) 65.1 (9.4) 0.25 
INTERMACS Profile at Implantation         
1 63 (20) 31 32 0.69 
2 83 (27) 41 42 0.66 
3 99 (32) 50 49 0.82 
4 62 (20) 36 26 0.24 
5-7 2 (1) 0 2 0.14 
Comorbidities         
Hypertension, N (%) 186 (60.2) 102 (64.2) 83 (55.3) 0.20 
Diabetes Mellitus, N (%) 123 (39.8) 66 (41.5) 58 (38.7) 0.73 
Obstructive Sleep Apnea, N (%) 92 (29.8)  52 (32.7) 40 (26.7) 0.27 
COPD, N (%) 68 (22) 43 (27) 25 (16.7) 0.039 
Chronic Kidney Disease, N (%) 99 (32) 57 (35.8) 42 (28) 0.18 
Prior Median Sternotomy, N (%) 100 (32) 53 (33.3) 47 (31.3) 0.72 
Ventricular Tachycardia, N (%) 137 (44.3) 100 (62.9) 37 (24.7) <0.0001 
Atrial Fibrillation, N (%) 171 (55.3) 114 (71.7) 57 (38) <0.0001 
Lab Values         
Hemoglobin, g/dL (SD) 11.8 (2.0) 11.7 (2) 12 (2) 0.12 
Creatinine, mg/dL (SD) 1.3 (0.4) 1.37 (0.45) 1.25 (0.41) 0.01 
Albumin, g/dL (SD) 3.3 (0.6) 3.27 (0.55) 3.41 (0.55) 0.04 
RDW, % (SD) 15.9 (2.5) 15.9 (2.4) 15.8 (2.7) 0.39 
Pre-LVAD Hemodynamics         
Right Atrial Pressure, mmHg (SD) 12.5 (6.3) 12.8 (6.4) 12.3 (6.2) 0.56 
Pulmonary Artery Saturation, % (SD) 53 (10.3) 53.2 (10.7) 52.7 (10) 0.65 
Wedge Pressure, mmHg (SD) 24 (8.9) 23.7 (9.1) 24.4 (8.7) 0.32 
Fick Cardiac Index, L/min/m2 (SD) 2 (0.5) 2.09 (0.6) 1.97 (0.5) 0.057 
 
Y= year; DT =destination therapy; BMI = body mass index; SD = standard deviation; BSA = body 
surface area; LVEF = left ventricular ejection fraction; LVIDd= left ventricular internal dimension in 
diastole; RDW = red blood cell distribution width; TSH= thyroid stimulating hormone; ICD= 
implantable cardioverter defibrillator; CRT-D= cardiac resynchronization therapy-defibrillator 
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Of the 290 patients who survived to discharge, 143 (49.3%) patients had CRT-D in 
place, with no new patients receiving or being upgraded to CRT-D following LVAD 
implantation. A total of 135 (46.6%) patients had an ICD in place at the time of 
discharge compared to 83 (28.6%) patients at the time of index admission. Nine 
patients were discharged from the hospital without an ICD in place. ECGs were 
evaluated both pre- and post-LVAD implantation. A total of 76 patients had a non-
ventricularly paced ECG within 1 month prior to LVAD implantation and a non-
ventricularly paced ECG 3 or more months following LVAD implantation for 
comparison of intervals pre- and post-LVAD (Table 2). 
 
Table 2. Comparison of Non-Ventricular Paced ECG Intervals Pre- and Post-
LVAD Implantation 
 
 ECG Interval 
Average Pre-LVAD 
Duration, ms (SD) 
Average Post-LVAD 
Duration, ms (SD) 
P value (95% CI) 
PR 174.3 169.5 0.23 (-3.9-16.0) 
QRS 115.2 102.9 0.0001 (6.6-17.4) 
QT 393.9 406.4 0.14 (-29.2-4.2) 
QTc (Bazett) 485.6 466.8 0.0074 (5.2-32.5) 
 
 
Of the 309 patients in our study, 137 (44.3%) patients had documented NSVT or 
sustained VT prior to undergoing LVAD implantation. Thirty-nine (12.6%) patients 
were admitted to the hospital for their index admission because of VT or had VT 
during their admission, but prior to undergoing LVAD implantation. The most 
common pre- and post-LVAD rhythm was a ventricular-paced rhythm (Vpaced) 
with 118 (38.2%) patients having this as their primary rhythm prior to implantation 
and 111 (35.9%) having this as their primary rhythm post-implantation (Table 3).  
 
Table 3. Most Common Heart Rhythms Pre- and Post-LVAD Implantation 
 
 
Atrial fibrillation or atrial flutter were present in 171 (55.3%) patients prior to LVAD 
implantation and 120 (38.8%) patients post-LVAD, but these were the primary 
rhythm in only 17 (5.5%) patients pre-LVAD and 21 (6.8%) patients post-LVAD.  
A total of 98 (31.7%) patients had a ventricular arrhythmia following LVAD 
implantation. Ninety-three (94.9%) had VT only, 2 (2%) patients had VF only, and 
3 (3%) patients had both VT and VF following implantation. Of the 98 patients who 
had a ventricular arrhythmia post-LVAD, 48 (49%) patients had a history of 
ventricular arrhythmia pre-LVAD, while the other 50 (51%) patients had a 
Rhythm Pre-LVAD, N (%) Post-LVAD, N (%) 
Ventricular Paced 118 (38.1) 111 (36.0) 
Normal Sinus Rhythm 106 (34.3) 103 (33.3) 
Sinus Tachycardia 48 (15.5)  33 (10.7) 
Afib/Aflutter 17 (5.5) 21 (6.8) 
Unknown Rhythm 8 (2.6) 37 (12.0) 
Atrial Paced 7 (2.3) 4 (1.3) 
Sinus Bradycardia 5 (1.6) 0 (0.0) 
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ventricular arrhythmia only after LVAD. While 12 (3.9%) patients underwent VT 
ablation prior to LVAD implantation, only 1 (0.3%) patient had a VT ablation in the 
post-implantation period. Frequent post-implantation VT and limited VT ablation 
led to frequent prescribing of antiarrhythmics post-LVAD, with 225 (72.8%) 
patients being prescribed at least one antiarrhythmic in the post-implantation 
period. Only 24 (7.8%) patients were on multiple antiarrhythmic concurrently 
following LVAD implantation. A total of 161 (52.1%) patients were on amiodarone 
within 2 years prior to LVAD implantation and 158 (51.4%) patients who survived 
to discharge were continued on amiodarone at the time of their dismissal. Drug 
utilization frequencies pre- and post-implantation are listed in Table 4. 
 
Table 4. Drug Utilization Pre- and Post-LVAD Implantation 
 
Medication Utilization 
On beta blocker at time of LVAD admission, N (%) 225 (72.8) 
On amiodarone within 2 years prior to LVAD, N (%) 159 (51.4) 
Discharged on beta blocker post-LVAD, N (%) 76 (27.7) 
Discharged on digoxin post-LVAD, N (%) 110 (40.1) 
Discharged on amiodarone post-LVAD, N (%) 158 (57.7) 
On beta blocker 3 months post-LVAD, N (%) 89 (34.9) 
Antiarrhythmic therapy post-LVAD, N (%) 225 (72.8) 
Amiodarone use at any point post-LVAD, N (%) 212 (68.6) 
Post-LVAD Mexiletine, N (%) 18 (5.8) 
Post-LVAD Sotalol, N (%) 12 (3.9) 
Post-LVAD Dofetilide, N (%) 5 (1.6) 
Post-LVAD Quinidine, N (%) 2 (0.6) 
 
On univariate analysis, amiodarone was associated with increased mortality, with 
a hazard ratio of 1.699 (P=0.0193, CI 1.090-2.648). The Kaplan-Meier survival 
curve is displayed in Figure 1. Other variables associated with increased mortality 
include age at implant (p=0.0006), creatinine (p=0.0042), albumin (p=0.022), RDW 
(p=0.0469), and prior median sternotomy (p<0.0001) (Table 5).  
 
Table 5. Univariate Analysis of Pre-LVAD Variables and Their Impact On 
Survival 
 
 
 
Variable 
Hazard 
Ratio 
P-Value 
95% Confidence 
Interval 
Pre-LVAD amiodarone 1.699 0.019 1.09-2.65 
Age at Implant 1.04 0.0006 1.02-1.06 
BMI at Implant 0.99 0.68 0.96-1.03 
Pre-LVAD Creatinine 1.97 0.004 1.24-3.14 
Pre-LVAD Albumin 0.63 0.022 0.43-0.94 
Pre-LVAD RDW 1.08 0.047 1.001-1.17 
Pre-LVAD COPD 1.13 0.63 0.69-1.84 
Prior Pre-LVAD sternotomy 2.30 <0.0001 1.57-3.73 
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Figure 1. Kaplan-Meier survival curve showing worse post-implantation 
survival in patients who were on amiodarone prior to LVAD compared to 
those who were not on Amiodarone 
 
On multivariate analysis, only albumin (p=0.03) and prior median sternotomy 
(p<0.001) remained independent predictors of survival (Table 6). The use of 
amiodarone prior to LVAD implantation did not have an impact on duration of 
intubation following LVAD placement (p=0.43), length of stay following LVAD 
implantation (p=0.10), or number of readmissions (p=0.57). 
 
Table 6. Multivariate Analysis of Pre-LVAD Variables and Their Impact on 
Survival 
 
 
 
Variable 
Hazard 
Ratio 
P-Value 
95% Confidence 
Interval 
Pre-LVAD amiodarone use 1.5 0.09 0.94-2.38 
Age at Implant 1.0 0.16 0.99-1.04 
Pre-LVAD Creatinine 1.5 0.11 0.91-2.57 
Pre-LVAD Albumin 0.6 0.03 0.42-0.96 
Pre-LVAD RDW 1.0 0.35 0.96-1.1 
Prior Pre-LVAD sternotomy 2.3 <0.001 1.41-3.62 
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Discussion 
 
This single center, retrospective study showed that patients with a history of 
amiodarone use within two years of LVAD implantation were at increased risk of 
post-operative mortality, as were older patients, those with prior median 
sternotomies, low albumin, and high creatinine and RDW. On multivariate analysis, 
only albumin and prior median sternotomy remained independent predictors of 
mortality. This study also showed that mechanical unloading of the heart leads to a 
significant reduction in the QRS and QTc intervals. We found that ventricular 
tachycardia is common in end-stage heart failure, both pre- and post-LVAD 
implantation and amiodarone is the most commonly used antiarrhythmic used to 
treat arrhythmias before and after LVAD implantation. 
 
ECGs were evaluated both pre- and post-LVAD implantation for rhythm and 
interval durations. A total of 76 patients had non-ventricularly paced ECGs both 
pre- and post-LVAD implantation available for comparison. We found a statistically 
significant decrease in QRS duration (p=0.0001) as well as a significant decrease 
in the QTc interval (p=0.0074) from pre- to post-implantation. Harding and 
colleagues previously looked at changes in ECG intervals pre- and post-LVAD and 
found a significant decrease in the QRS immediately post-implant (within 6 hours), 
but this was not sustained more than a week post-LVAD.6 It has been 
hypothesized that since changes in conduction velocity after cardiac distension 
have not been identified, possible decreases in cardiac dimensions post-LVAD 
lead to an overall decrease in conduction distance and thus a decrease in QRS 
duration. This same group has also noted a significant increase in QT and QTc 
intervals in the immediate post-implantation period followed by a significant 
decrease in these intervals more than 1-week post-implantation.7, 8 While we did 
not evaluate ECGs in the immediate post-implantation period, we did identify a 
significant decrease in the QTc interval when evaluating a more delayed effect of 
mechanical unloading on ECG characteristics. Action potential prolongation has 
previously been shown to be a common abnormality in failing hearts and it has 
been hypothesized that mechanical unloading of failing hearts reverses this 
characteristic resulting in decreased action potential durations and thus, shorter 
QTc intervals. 9 
 
The primary rhythm identified on ECG and telemetry review in our study was V-
paced, both in the pre-LVAD (38.1%) and post-LVAD (36%) time periods. Martinez 
and colleagues have previously shown a similar prevalence of V-paced rhythm in 
their pre-implantation population at 40%, but the percentage of patients primarily 
V-paced following implantation increased to 79% in their study. Normal sinus 
rhythm and sinus tachycardia were the next two most common rhythms both pre- 
and post-implantation. There was a low number of patients without ECGs obtained 
in the pre-LVAD period (2.8%) and significantly higher in the post-implantation 
period (12%). Martinez and colleagues have emphasized the importance of 
obtaining an ECG in every patient in the post-implantation period to establish a 
new baseline.10 While most of the rhythm monitoring in the post-implantation 
period is done via ICD interrogation, ECGs are still clinically useful for monitoring 
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of the QT/QTc duration, especially in patients receiving antiarrhythmic therapy and 
potentially identifying patients at risk for ventricular arrhythmias.  
 
Our study showed that 31.3% of patients had VT following LVAD implantation, 
which is in line with previous studies that have found that VT occurred anywhere 
from 22-59% following LVAD implantation.11, 12 We also found that 44.3% of 
patients had at least one episode of VT prior to undergoing LVAD implantation with 
12.6% of patients having an episode of VT leading to index admission or during 
the in-hospital evaluation prior to implantation. Afib was a problem for 55.3% of 
patients prior to LVAD, but only 38.8% of patients continued to have issues with 
afib following implantation. A previous study by Enriquez and colleagues showed a 
slightly higher incidence of afib post-LVAD at 51.9%.13 They also found that 
persistent afib was an independent predictor of death and hospitalization for heart 
failure. While previous studies have shown that ventricular arrhythmias tend to 
occur within the first week to month following LVAD-implantation,4, 14 timing of 
ventricular arrhythmias was not evaluated in our study.  
 
We found that 49% of patients had CRT in place prior to undergoing LVAD 
implantation and this did not change following implantation. While only 26.9% of 
patients had a single-chamber ICD in place prior to LVAD implantation, 52 new 
devices were implanted in the post-implantation period. In our study, 75.7% of 
patients had an ICD in place (whether biventricular or single chamber) at the time 
of LVAD implantation. Previous studies have had significant variability in the 
number of patients with ICDs in place prior to LVAD implantation, ranging 
anywhere from 18.8% and 31.1%, up to 75.5%.15-17 Our study is more in line with 
data presented by Enriquez and colleagues, with 75.7% having an ICD in place at 
the time of LVAD, likely indicating that our patients tend to have more chronic 
heart failure with attempts at optimizing their medical and device therapy prior to 
proceeding with LVAD and transplant evaluation.17 
 
There was a total of nine patients who were discharged without an ICD in place. 
The reasons for not placing an ICD in these patients varied and included: 1.) prior 
ICD explantation due to infection, 2.) two with improvement in left ventricular 
function or decrease in ectopy prior to discharge, 3.) electrophysiology study 
showing no inducible VT, 4.) receipt of heart transplantation prior to initial 
discharge, 5.) concern for hypotension with anesthesia and risk for neurologic 
event, and 6.) three patients with unclear documentation as to why no ICD was 
placed. To our knowledge, there are no studies investigating the use of 
intracardiac EP studies in the post-LVAD population to assess low-risk patients for 
inducible VT to help direct ICD placement. A recent meta-analysis of six 
observational studies totaling 937 patients showed ICD use in LVAD patients was 
associated with a significant reduction in mortality, but in a subgroup analysis of 
361 patients with continuous flow LVADs, there was not a statistically significant 
decrease in mortality following LVAD implantation with an ICD in place.18 
 
Antiarrhythmic medications are frequently used to treat both atrial and ventricular 
arrhythmias in advanced heart failure patients both before and after LVAD 
implantation. We found that 72.8% of patients were on at least one antiarrhythmic 
medication in the post-implantation period. Amiodarone was the most commonly 
used antiarrhythmic, with 94% of the patients requiring antiarrhythmic therapy 
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being on amiodarone. Amiodarone use was equally frequent in the pre-LVAD 
period (52%) and in the post-LVAD period, with 51% of patients being discharged 
from the hospital on amiodarone following LVAD implantation. Previous studies 
have also shown that amiodarone is the most commonly used antiarrhythmic in the 
post-LVAD setting, with 66.7-75% of antiarrhythmic utilization for VT being done 
with amiodarone.11, 14 The utilization of beta-blockers at discharge and 3 months 
following LVAD implantation is low in our institution (Table 4), historically due to 
concern for increased risk of right ventricular failure. Wever-Pinzon and colleagues 
recently showed that patients on a beta-blocker at 12 months following LVAD 
implantation were more likely to experience cardiac recovery and small, 
retrospective studies have shown it may improve post-implantation survival and 
does not appear to increase the number of heart failure readmissions. 19-21 
 
The side effects of long-term amiodarone use have been documented since the 
early 1980s and primarily involve the thyroid gland, liver, lungs, skin, and cornea.22 
Given amiodarone's frequent usage in patients undergoing heart transplant 
evaluation because of increased incidence of ventricular arrhythmias, a few 
studies over the last 20 years have looked at postoperative outcomes following 
heart transplantation in patients who received amiodarone in the pre- and post-
operative period. Chin et al published a retrospective review in 1999 of 106 
consecutive heart transplants and found that patients who had received 
amiodarone for more than 4 weeks pre-transplant had higher mortality at 1 year.23 
Blomberg and colleagues found that patients who had received amiodarone within 
3 months of heart transplant had decreased survival post-transplant, required 
longer periods of postoperative ventilatory support, and were more likely to 
experience bleeding complications.24 More recently, Cooper and colleagues 
published a retrospective cohort analysis of 14,955 patients from the International 
Society for Heart and Lung Transplantation registry that again found that patients 
treated with amiodarone prior to heart transplant had higher 1-year mortality but 
did not find increased risks of early graft failure, retransplantation, or 
rehospitalizations.25 To our knowledge, there have not been prior reports looking at 
amiodarone utilization prior to LVAD implantation and its impact on post-operative 
outcomes.  
 
Despite 137 patients having VT prior to LVAD implantation and 96 patients having 
VT post-implantation, only 12 patients underwent VT ablation pre-LVAD and 1 
patient post-LVAD at our institution. Per-LVAD and post-LVAD VT ablation have 
previously been well described in several studies. Garan and colleagues looked at 
224 patients who underwent LVAD placement and identified 7 patients who 
underwent EP study and VT ablation following LVAD implantation.26 Multiple VTs 
were identified and ablated, with 5 of the 7 patients having a significant reduction 
in their VT following ablation.26 A larger study evaluated 611 patients who 
underwent LVAD implantation over almost a 20-year period and identified 21 
patients who underwent post-LVAD EP study. Of the 20 patients who had 
inducible VT, 18 had acute ablative success with 7 patients having recurrent VT 
and underwent a repeat procedure.27 Amiodarone use decreased in both studies 
post-ablation with each study noting very few procedural complications and low 
post-procedural morbidity and mortality. Intraoperative ablation has been 
evaluated in a study of 5 patients who underwent peri-LVAD open chest hybrid 
epicardial mapping and VT ablation with 3 of the 5 patients having acute 
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procedural success and no arrhythmia related deaths in any of the patients over a 
mean follow-up period of 363 ± 368 days.28 
 
On a univariate analysis, we found that patients on amiodarone within two years 
prior to LVAD implantation had an increased risk of mortality, with a HR of 1.7 and 
p=0.019. We also found that pre-implantation albumin, creatinine, and RDW as 
well as patient's age and history of prior median sternotomy predicted an 
increased risk of mortality on univariate analysis. Our findings confirm prior studies 
showing increased risk of mortality with lower albumin, higher RDW, worse renal 
function, and increasing age at the time of implantation.29-34 Our findings of 
increased risk of mortality in patients with a history of a previous sternotomy prior 
to LVAD implantation conflict with a recent study published by Papathanasiou and 
colleagues. In their study of 112 patients who underwent implantation with 
HeartWare (HeartWare International Inc., Framingham, MA), they found no 
difference in survival rate at 6 months (p=0.37) in patients who had a history of 
prior median sternotomy at the time of LVAD implantation compared to those 
without prior sternotomy.35 In our study, history of prior median sternotomy was the 
strongest predictor of increased mortality (p<0.0001) and on multivariate analysis 
remained an independent predictor of mortality (p=0.0007). Pre-LVAD albumin 
(p=0.0302) was the only other independent predictor of increased mortality on 
multivariate analysis, similar to findings previously described by Kato and 
colleagues.  
 
There are several limitations to our study. This is a single-center experience 
involving both DT and BTT patients. Our analysis is retrospective in nature with a 
limited patient population. In some cases, pre- and post-LVAD ECGs were not 
available and prevented full evaluation of the entire patient population. Transition 
to a new electronic health record during the study period may have created 
difficulties in transfer of information between the systems as well as documentation 
early on. 
 
In summary, the present study shows a significant decrease in QRS and QTc 
intervals post-LVAD implantation. Amiodarone was frequently used in both the pre- 
and post-LVAD setting to treat both atrial and ventricular arrhythmias. Amiodarone 
use may increase post-LVAD mortality. Despite the incidence of VT both before 
and after LVAD implantation, ablation was performed relatively infrequently in our 
patient population. With numerous studies showing increased mortality following 
heart transplant in patients who received pre-transplant amiodarone and our study 
showing pre-LVAD amiodarone potentially being associated with worse survival on 
univariate analysis, further studies need to be done investigating amiodarone 
reduction strategies and if ablation for recurrent VT is a superior strategy in 
patients undergoing transplant evaluation or with LVADs as bridge to transplant.  
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